Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Texas: - UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- Lyndon Baines Johnson General Hospital — Houston, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in Texas: - MD Anderson in The Woodlands — Conroe, Texas
- Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- M D Anderson Cancer Center — Houston, Texas
- MD Anderson West Houston — Houston, Texas
Phase 3 Recruiting Industry
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in c…
Sponsor: Eli Lilly and Company
NCT ID: NCT07218380
Sites in Texas: - USO-Texas Oncology-Central/South Texas — Austin, Texas
- World Research Link — Baytown, Texas
- Parkland Health and Hospital System — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 3 Recruiting Industry
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06510374
Sites in Texas: - Urology Clinics of North Texas PLLC (Dallas) — Dallas, Texas
- Houston Methodist Hospital (Houston) — Houston, Texas
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in Texas: - Urology Austin — Austin, Texas
- Urology Clinics of North Texas — Dallas, Texas
- UT Southwestern — Dallas, Texas
- Houston Metro Urology — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07106762
Sites in Texas: - Local Institution - 0249 — Abilene, Texas
- Local Institution - 0187 — Austin, Texas
Phase 3 Recruiting Industry
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and …
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06545955
Sites in Texas: - Urology Austin — Austin, Texas
- Urology Clinics of North Texas PLLC (Dallas) — Dallas, Texas
- University of Texas Southwestern Medical Center - Urology Clinic — Dallas, Texas
- Houston Methodist Hospital (Houston) — Houston, Texas
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Sites in Texas: - Research Site — Austin, Texas
- Research Site — Dallas, Texas
- Research Site — Dallas, Texas
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Gué…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06919965
Sites in Texas: - Urology Austin — Austin, Texas
- Urology San Antonio PA dba USA Clinical Trials — San Antonio, Texas
Phase 3 Recruiting Academic/Other
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol …
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT04865939
Sites in Texas: - University of Texas Southwestern Medical Center — Dallas, Texas
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Texas: - Saint Joseph Regional Cancer Center — Bryan, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
Phase 2 Recruiting Industry
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that …
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04879329
Sites in Texas: - Baylor Scott and White Research Institute — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Baylor Scott & White Medical Center - Temple — Temple, Texas
Phase 2 Recruiting NIH
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer. Standard of care therapy inc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061964
Sites in Texas: - Parkland Memorial Hospital — Dallas, Texas
- UT Southwestern Simmons Cancer Center - RedBird — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Sponsor: CG Oncology, Inc.
NCT ID: NCT06567743
Sites in Texas: - Amarillo Urology Research — Amarillo, Texas
- UPNT Research Institute, LLC — Arlington, Texas
- Urology Austin, PLLC (Urology America) — Austin, Texas
- Urology Clinics of North Texas, PLLC — Dallas, Texas
- UT Southwestern Medical Center — Dallas, Texas
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…
Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in Texas: - Urology Austin — Austin, Texas
- UT Southwestern Medical Center — Dallas, Texas
- Houston Metro Urology — Houston, Texas
- Houston Methodist Hospital - Department of Urology — Houston, Texas
- University of Texas - MD Anderson Cancer Center — Houston, Texas
Phase 2 Recruiting Industry
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101…
Sponsor: Protara Therapeutics
NCT ID: NCT05951179
Sites in Texas: - Amarillo Urology Research — Amarillo, Texas
- Urology Partners of North Texas — Arlington, Texas
- Urology Austin, LLC — Austin, Texas
- Houston Metro Urology — Houston, Texas
- Houston Methodist Hospital — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissue…
Sponsor: Pfizer
NCT ID: NCT07421700
Sites in Texas: - Texas Oncology - Central/South Texas — Austin, Texas
- Texas Oncology - Austin — Austin, Texas
- Texas Oncology - Central/South Texas — Austin, Texas
- Texas Oncology - Central/South Texas — Austin, Texas
- Texas Oncology - Central South — Austin, Texas
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas: - New Experimental Therapeutics - NEXT Oncology — Austin, Texas
- UTSW - Moody Outpatient Center - Parkland Health — Dallas, Texas
- UT Southwest Simmons Cancer Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and pre…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05316155
Sites in Texas: - Urology Austin — Austin, Texas
- Urology San Antonio Research — San Antonio, Texas
Phase 2 Recruiting Industry
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Sponsor: Tyra Biosciences, Inc
NCT ID: NCT06995677
Sites in Texas: - Baylor College of Medicine — Houston, Texas
- Urology San Antonio — San Antonio, Texas
Phase 2 Recruiting Industry
Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06833073
Sites in Texas: - Texas Oncology-Austin Central ( Site 0107) — Austin, Texas
- Urology Austin, PLLC ( Site 0109) — Austin, Texas
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Texas: - The University of Texas, MD Anderson Cancer Center — Houston, Texas
- UT Health Mays Cancer Center — San Antonio, Texas
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of…
Sponsor: Tasca Therapeutics
NCT ID: NCT07030257
Sites in Texas: - NEXT Oncology - Dallas — Dallas, Texas
- START San Antonio — San Antonio, Texas
Phase 2 Recruiting Industry
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…
Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Texas: - The University of Texas MD Anderson Cancer Center — Houston, Texas
Phase 1, Phase 2 Recruiting Industry
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in co…
Sponsor: Aulos Bioscience, Inc.
NCT ID: NCT05267626
Sites in Texas: - Texas Oncology (Balcones) - SCRI — Austin, Texas
- MD Anderson Cancer Center — Houston, Texas
- START South Texas Accelerated Research Therapeutics — San Antonio, Texas